EMD Serono posted on LinkedIn.
“News: Today we entered a strategic collaboration with Jiangsu Hengrui Pharmaceuticals. This agreement aims to strengthen our robust internal oncology pipeline in DNA damage response (DDR) inhibition and antibody-drug conjugates (ADC) to deliver on our ambition to advance therapeutic options for patients with difficult-to-treat cancers. Learn more here.”
Source: EMD Serono/LinkedIn